---
title: "Nasdaq files Form 25 to delist Avenue Therapeutics common stock"
url: "https://aibio.space/news/nasdaq-files-form-25-delist-avenue-therapeutics-common-stock/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-07-18"
section: "Listings"
tickers: "OTC:ATXI"
source: "https://www.sec.gov/Archives/edgar/data/1644963/000135445725000696/xslF25X02/primary_doc.xml"
summary: "The Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration."
---

By the aibio.space news desk.

Sources

- [Avenue Therapeutics, Inc. 25-NSE (2025-07-18)](https://www.sec.gov/Archives/edgar/data/1644963/000135445725000696/xslF25X02/primary_doc.xml)

[ATXI](https://aibio.space/companies/avenue-therapeutics/)

2025-07-18

# Nasdaq files Form 25 to delist Avenue Therapeutics common stock

Tickers [ATXI](https://aibio.space/companies/avenue-therapeutics/)

The Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.

## Key facts

- **Company**: Avenue Therapeutics, Inc. (OTC: ATXI)

- **News type**: Listings

- **Primary source**: [Avenue Therapeutics, Inc. 25-NSE (2025-07-18)](https://www.sec.gov/Archives/edgar/data/1644963/000135445725000696/xslF25X02/primary_doc.xml)

*A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

The Nasdaq Stock Market LLC filed a Form 25-NSE with the Securities and Exchange Commission on 2025-07-18 to remove the common stock of Avenue Therapeutics, Inc. from listing and registration on the exchange.

A Form 25 is the notice an exchange files with the SEC when a class of securities is removed from listing and registration. Nasdaq filed this one under 17 CFR 240.12d2-2(b), the provision an exchange cites when it removes a security under its own rules.

The notice was filed for Nasdaq by a member of its hearings staff, whose title is listed as Hearings Advisor. It identifies the company as Avenue Therapeutics, Inc., at 2 Gansevoort Street, 9th Floor, New York, with Commission file number 333-217552. The only class of securities named in the form is the company's common stock.

The form is a short exchange notice. Readers can see the original on the [SEC website](https://www.sec.gov/Archives/edgar/data/1644963/000135445725000696/xslF25X02/primary_doc.xml).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ATXI

Avenue Therapeutics, Inc.

OTC · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/nasdaq-files-form-25-delist-avenue-therapeutics-common-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nasdaq files Form 25 to delist Avenue Therapeutics common stock", 2025-07-18, https://aibio.space/news/nasdaq-files-form-25-delist-avenue-therapeutics-common-stock/